Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03977662 · ClinicalTrials.gov registry record · Phase 1
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes
A Phase 1 study, sponsored by Peter Stock.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03977662 is a Phase 1 study that has completed, run by Peter Stock. The registered enrollment target is 4 participants.
The verdict
NCT03977662, a Phase 1 study, has completed, sponsored by Peter Stock.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective is to test the hypothesis that co-transplantation of allogeneic PTG with adult pancreatic islets (derived from same deceased donor) in the IM site in people with Type 1 diabetes with functioning kidney and/or liver transplants is safe, allows islet engraftment, and leads to insulin independence.
Interventions
- COMBINATION_PRODUCT Co-transplantation of PTG with pancreatic islets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03977662
The ClinicalTrials.gov registry entry for NCT03977662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter Stock, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Co-transplantation of PTG with pancreatic islets is the first listed.
NCT03977662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03977662 about?
NCT03977662 is a clinical study titled "Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes". The primary objective is to test the hypothesis that co-transplantation of allogeneic PTG with adult pancreatic islets (derived from same deceased donor) in the IM site in people with Type 1 diabetes with functioning kidney and/or liver transplants is safe, allows islet engraftment, and leads to ins...
What is the current status of trial NCT03977662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-07-01. Estimated completion is 2026-01-31.
What interventions are being tested in trial NCT03977662?
The interventions under investigation include: Co-transplantation of PTG with pancreatic islets (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03977662?
This trial is sponsored by Peter Stock, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.